CL2013003400A1 - Forma cristalina 2 de ciclosporina a e hidrato no-estequiométrico de la misma; composición farmacéutica que la comprende, útil para tratar un estado de ojo seco acuoso deficiente, uveitis, endoftalmitis facoanafiláctica y queratoconjuntivitis seca. - Google Patents

Forma cristalina 2 de ciclosporina a e hidrato no-estequiométrico de la misma; composición farmacéutica que la comprende, útil para tratar un estado de ojo seco acuoso deficiente, uveitis, endoftalmitis facoanafiláctica y queratoconjuntivitis seca.

Info

Publication number
CL2013003400A1
CL2013003400A1 CL2013003400A CL2013003400A CL2013003400A1 CL 2013003400 A1 CL2013003400 A1 CL 2013003400A1 CL 2013003400 A CL2013003400 A CL 2013003400A CL 2013003400 A CL2013003400 A CL 2013003400A CL 2013003400 A1 CL2013003400 A1 CL 2013003400A1
Authority
CL
Chile
Prior art keywords
uveitis
treating
useful
pharmaceutical composition
crystalline form
Prior art date
Application number
CL2013003400A
Other languages
English (en)
Spanish (es)
Inventor
Anuradha V Gore
Richards S Graham
Scott W Smith
Ke Wu
Kiomars Karami
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2013003400A1 publication Critical patent/CL2013003400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2013003400A 2011-05-27 2013-11-26 Forma cristalina 2 de ciclosporina a e hidrato no-estequiométrico de la misma; composición farmacéutica que la comprende, útil para tratar un estado de ojo seco acuoso deficiente, uveitis, endoftalmitis facoanafiláctica y queratoconjuntivitis seca. CL2013003400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
CL2013003400A1 true CL2013003400A1 (es) 2014-08-18

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003400A CL2013003400A1 (es) 2011-05-27 2013-11-26 Forma cristalina 2 de ciclosporina a e hidrato no-estequiométrico de la misma; composición farmacéutica que la comprende, útil para tratar un estado de ojo seco acuoso deficiente, uveitis, endoftalmitis facoanafiláctica y queratoconjuntivitis seca.

Country Status (19)

Country Link
US (4) US8772245B2 (cg-RX-API-DMAC7.html)
EP (2) EP2714720B1 (cg-RX-API-DMAC7.html)
JP (1) JP6163482B2 (cg-RX-API-DMAC7.html)
KR (1) KR102079402B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649108B (cg-RX-API-DMAC7.html)
AR (1) AR086586A1 (cg-RX-API-DMAC7.html)
AU (4) AU2012262513B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030554B1 (cg-RX-API-DMAC7.html)
CA (1) CA2836946C (cg-RX-API-DMAC7.html)
CL (1) CL2013003400A1 (cg-RX-API-DMAC7.html)
IL (2) IL229475A0 (cg-RX-API-DMAC7.html)
MX (1) MX362271B (cg-RX-API-DMAC7.html)
MY (1) MY180581A (cg-RX-API-DMAC7.html)
RU (1) RU2602062C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201607344UA (cg-RX-API-DMAC7.html)
TW (1) TWI554522B (cg-RX-API-DMAC7.html)
UA (1) UA113627C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012166610A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308665B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102029513B1 (ko) * 2011-11-15 2019-10-07 알러간, 인코포레이티드 사이클로스포린 제2형의 지속 작용 제형
JP6363506B2 (ja) 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
CN108714137B (zh) * 2011-11-15 2022-02-01 阿勒根公司 环孢菌素a形式2的可热压性悬浮液
CN104039813B (zh) 2011-11-15 2017-08-29 阿勒根公司 环孢菌素a形式2及其制备方法
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
RU2713953C2 (ru) * 2014-07-18 2020-02-11 Аллерган, Инк. Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
US12037415B2 (en) * 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
US20240342086A1 (en) * 2021-08-20 2024-10-17 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
US20260132169A1 (en) 2022-10-20 2026-05-14 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
CN120731215A (zh) 2023-03-20 2025-09-30 中外制药株式会社 用于产生环肽的共晶的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
CN101687013A (zh) * 2007-05-04 2010-03-31 阿勒根公司 环孢菌素在治疗具有人工晶状体的患者中的用途
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物

Also Published As

Publication number Publication date
JP2014515372A (ja) 2014-06-30
ZA201308665B (en) 2014-07-30
AU2019204192A1 (en) 2019-07-04
BR112013030554B1 (pt) 2020-12-15
NZ719272A (en) 2017-10-27
US8772245B2 (en) 2014-07-08
CA2836946C (en) 2017-08-01
US20130023482A1 (en) 2013-01-24
AU2012262513A1 (en) 2013-12-12
UA113627C2 (xx) 2017-02-27
TWI554522B (zh) 2016-10-21
AR086586A1 (es) 2014-01-08
EP3521302A1 (en) 2019-08-07
RU2602062C2 (ru) 2016-11-10
US20140315827A1 (en) 2014-10-23
BR112013030554A2 (pt) 2016-09-06
AU2019204192B2 (en) 2021-02-04
US9206228B2 (en) 2015-12-08
MY180581A (en) 2020-12-02
JP6163482B2 (ja) 2017-07-12
WO2012166610A1 (en) 2012-12-06
US20160083432A1 (en) 2016-03-24
AU2017265008A1 (en) 2017-12-07
MX362271B (es) 2019-01-10
KR20140047054A (ko) 2014-04-21
NZ618213A (en) 2016-05-27
CA2836946A1 (en) 2012-12-06
IL229475A0 (en) 2014-01-30
AU2016203990A1 (en) 2016-06-30
EP2714720A1 (en) 2014-04-09
EP2714720B1 (en) 2018-12-26
RU2013155033A (ru) 2015-07-20
CN103649108A (zh) 2014-03-19
US20210269484A1 (en) 2021-09-02
SG10201607344UA (en) 2016-10-28
KR102079402B1 (ko) 2020-02-19
TW201311730A (zh) 2013-03-16
MX2013013855A (es) 2014-02-17
IL290158A (en) 2022-03-01
AU2012262513B2 (en) 2016-03-17
CN103649108B (zh) 2017-03-29

Similar Documents

Publication Publication Date Title
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX382899B (es) Composiciones y métodos que comprenden variantes de proteasa termolisina.
MY181898A (en) Heterocyclic compounds and uses thereof
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
IL229072A0 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
EA201291394A1 (ru) Твердые композиции
ZA201307815B (en) N-(1,3,4-oxadiazol-2-yl)arylcarboxamides and use thereof as herbicides
MX2015002040A (es) Baricitinib deuterado.
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
EA201591420A1 (ru) Гетероарильные соединения и их применение
PL3003038T3 (pl) Pochodne 2H-1,2,3-triazoli jako inhibitory zwłóknienia
CO6821886A2 (es) Inhibidores potentes y selectivos de nav1.3 y nav1.7
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
IN2015DN00598A (cg-RX-API-DMAC7.html)
BR112014007396A2 (pt) processo para produzir uma composição de mistura seca de poli(cloreto de vinila), composição e artigo
UY34034A (es) Triazolopiridinas
EP2712291A4 (en) N1 AND N2 CARBAMOYL-1,2,3-TRIAZOL SERINE HYDROLASE INHIBITORS AND METHOD THEREFOR
EA201370149A1 (ru) Антагонисты рецептора
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
MX357477B (es) Composiciones de limpieza de sal colina.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан